- ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301)
This study is testing a new medicine, bemarituzumab, for people with certain solid tumours that have a specific marker called FGFR2b overdue. It will look at how safe the medicine is and if it can shrink or stop the growth of these cancers.
France · Hungary · Romania - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours
This study is looking at two new medicines, Zejula (niraparib) and JEMPERLI (dostarlimab), for children and young people with solid tumours that have come back or not responded to other treatments. The main goal is to find a safe dose and see if they work together.
Spain · Germany · Czechia - not yet recruitingPhase I/II
A Phase I/IIa trial of NVG-222 in participants with solid tumours
This study is testing a new drug, NVG-222, for advanced solid tumours. It aims to find a safe dose, understand side effects, and see if it can shrink cancer. NVG-222 helps your immune system target and kill cancer cells, and includes a safety 'off-switch'.
United Kingdom · England - recruitingPHASE2
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
This study is looking into a new medicine called zongertinib for people with advanced cancers. It focuses on cancers where HER2, a protein, has changed. The goal is to see if zongertinib can help by blocking these changes in HER2.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
This study is testing a new medicine, AZD4956, alone or with another medicine, Saruparib, for people with advanced solid tumours. It aims to see if they are safe and how well they work, especially for tumours with certain genetic changes.
United States · Australia · Japan - recruitingPHASE1, PHASE2
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
This study is testing a new drug called ODM-212 for people with certain advanced solid cancers that haven't responded to other treatments. It aims to find the right dose and see if it helps. It's a first-time human study.
United States · Finland · France - active not recruitingPHASE2
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
This study looks at long-term brigimadlin treatment for people with solid tumours who were in an earlier study. We want to see how well patients tolerate this medicine over time, continuing to take it as tablets every three weeks.
United States · Argentina · Australia - recruiting
Tissue Collection Framework To Improve Outcomes In Solid Tumours
This study aims to understand why solid tumours spread and become resistant to treatment. Researchers will collect tissue samples from cancer patients to analyse them using advanced technologies. The goal is to discover new ways to improve cancer therapies and predict which treatments will work best.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This study is testing a cancer drug called atezolizumab in people with certain cancers that have specific genetic changes. Atezolizumab is already used for some cancers, and this study wants to see if it can help other types of cancer that share these same genetic features.
United Kingdom - recruitingPHASE1
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
This study is testing a new drug, OKN4395, alone and with an existing cancer treatment, pembrolizumab, for various solid tumours. The main goals are to check its safety, how well it's tolerated, and if it helps fight cancer.
United States · Australia · United Kingdom - authorisedPhase I and Phase II (Integrated)- First administration to humans
A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PTT-4256 (RAISIC-1: Relief of Acidic Immune Suppression In Cancer)
This study is testing a new medicine, PTT-4256, for people with solid cancers. Researchers want to see if it's safe, how it works in the body, and if it helps shrink tumours. It's an early-stage study, combining safety checks with initial effectiveness tests.
France · Spain